Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 2
2007 29
2008 25
2009 15
2010 12
2011 11
2012 22
2013 22
2014 25
2015 18
2016 18
2017 20
2018 15
2019 12
2020 12
2021 11
2022 8
2023 3
2024 8
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Matthews DR, et al. Lancet. 2019 Oct 26;394(10208):1519-1529. doi: 10.1016/S0140-6736(19)32131-2. Epub 2019 Sep 18. Lancet. 2019. PMID: 31542292 Clinical Trial.
In study period 1, patients received either the early combination treatment with metformin (stable daily dose of 1000 mg, 1500 mg, or 2000 mg) and vildagliptin 50 mg twice daily, or standard-of-care initial metformin monotherapy (stable daily dose of 1000 mg, 1500 mg, or 2 …
In study period 1, patients received either the early combination treatment with metformin (stable daily dose of 1000 mg, 1500 mg, or 2000 m …
Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes.
Bekiari E, Rizava C, Athanasiadou E, Papatheodorou K, Liakos A, Karagiannis T, Mainou M, Rika M, Boura P, Tsapas A. Bekiari E, et al. Endocrine. 2016 Jun;52(3):458-80. doi: 10.1007/s12020-015-0841-1. Epub 2015 Dec 29. Endocrine. 2016. PMID: 26714458 Review.
This systematic review and meta-analysis provides an update on the efficacy and safety of vildagliptin for treatment of type 2 diabetes mellitus (T2DM). We searched MEDLINE, COCHRANE, EMBASE and the drug manufacturer's website for randomised controlled trials of vildagl …
This systematic review and meta-analysis provides an update on the efficacy and safety of vildagliptin for treatment of type 2 diabet …
Efficacy and Cardiovascular Safety of DPP-4 Inhibitors.
Subrahmanyan NA, Koshy RM, Jacob K, Pappachan JM. Subrahmanyan NA, et al. Curr Drug Saf. 2021;16(2):154-164. doi: 10.2174/1574886315999200819150544. Curr Drug Saf. 2021. PMID: 32819262 Review.
These drugs have been available on the market for the management of type 2 diabetes mellitus (T2DM) for over a decade. Sitagliptin, linagliptin, vildagliptin, saxagliptin and alogliptin are widely available globally, whilst anagliptin, gemigliptin and teneliptin are used m …
These drugs have been available on the market for the management of type 2 diabetes mellitus (T2DM) for over a decade. Sitagliptin, linaglip …
Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus: An open-label comparative study.
Sharma V, Chawla S, Garg S, Singh B. Sharma V, et al. Sultan Qaboos Univ Med J. 2024 May;24(2):243-249. doi: 10.18295/squmj.1.2024.006. Epub 2024 May 27. Sultan Qaboos Univ Med J. 2024. PMID: 38828248 Free PMC article. Clinical Trial.
OBJECTIVES: This study aimed to evaluate the safety and efficacy of remogliflozin compared to vildagliptin as an add-on drug to metformin in type 2 diabetes mellitus (T2DM) treatment. ...RESULTS: The decrement in mean HbA1c levels was significantly higher in the remogliflo …
OBJECTIVES: This study aimed to evaluate the safety and efficacy of remogliflozin compared to vildagliptin as an add-on drug to metfo …
The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
Cai L, Cai Y, Lu ZJ, Zhang Y, Liu P. Cai L, et al. J Clin Pharm Ther. 2012 Aug;37(4):386-98. doi: 10.1111/j.1365-2710.2011.01323.x. Epub 2011 Dec 22. J Clin Pharm Ther. 2012. PMID: 22191695 Review.
Compared with placebo, treatment with 50 mg/day of vildagliptin caused neutral weight changes, while 100 mg/day of vildagliptin resulted in slight weight gain [0.95 kg (95% CI, 0.73-1.17 kg)]. ...The incidence of hypoglycaemia was low with vildagliptin, and t …
Compared with placebo, treatment with 50 mg/day of vildagliptin caused neutral weight changes, while 100 mg/day of vildagliptin …
The effect of vildagliptin versus metformin on hepatic steatosis in type 2 diabetic patients: a randomized controlled trial.
Mohamed AS, Ahmad HM, Sharawy MA, Kamel FMM. Mohamed AS, et al. BMC Pharmacol Toxicol. 2024 Dec 13;25(1):94. doi: 10.1186/s40360-024-00818-7. BMC Pharmacol Toxicol. 2024. PMID: 39673064 Free PMC article. Clinical Trial.
This study aimed to compare the effects of vildagliptin and metformin on hepatic steatosis in newly diagnosed T2D patients, using the Hepatic Steatosis Index (HSI) and ultrasound grading. ...The first group (117 patients) received 50 mg of vildagliptin orally twice …
This study aimed to compare the effects of vildagliptin and metformin on hepatic steatosis in newly diagnosed T2D patients, using the …
Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Bundhun PK, Janoo G, Teeluck AR, Huang F. Bundhun PK, et al. BMC Pharmacol Toxicol. 2017 Oct 23;18(1):66. doi: 10.1186/s40360-017-0175-0. BMC Pharmacol Toxicol. 2017. PMID: 29058622 Free PMC article. Review.
In this analysis, we aimed to systematically compare the adverse drug events which were observed with the use of vildagliptin versus pioglitazone or rosiglitazone respectively. METHODS: Online databases were searched for studies comparing vildagliptin with pioglitaz …
In this analysis, we aimed to systematically compare the adverse drug events which were observed with the use of vildagliptin versus …
The impact of vildagliptin as an add-on therapy on matrix metalloproteinase-14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non-alcoholic steatohepatitis: A randomized controlled trial.
ElKabbany ZA, Ismail EAR, Hamed ET, Elbarbary NS. ElKabbany ZA, et al. Diabetes Obes Metab. 2024 Dec;26(12):5857-5869. doi: 10.1111/dom.15958. Epub 2024 Sep 24. Diabetes Obes Metab. 2024. PMID: 39318059 Clinical Trial.

After 6 months, patients with T1DM on vildagliptin therapy had significantly lower glycated haemoglobin, lipid profile, hepatic steatosis index and TyG index, as well as MMP-14 (p < 0.001). CIMT, liver stiffness and CAP were significantly decreased post-therapy compared

…
After 6 months, patients with T1DM on vildagliptin therapy had significantly lower glycated haemoglobin, lipid profile, hepatic steat …
Vildagliptin vs. insulin treatment alone in diabetic acute coronary syndrome patients.
Dobrecky-Mery I, Sommer A. Dobrecky-Mery I, et al. Coron Artery Dis. 2021 Jan;32(1):4-9. doi: 10.1097/MCA.0000000000000901. Coron Artery Dis. 2021. PMID: 32310854 Clinical Trial.
We hypothesized that among hospitalized acute coronary syndrome (ACS) patients, the addition of vildagliptin to subcutaneous insulin therapy would reduce the risk of hypoglycemic events. ...Patients were divided into two randomized controlled groups: a subcutaneous rapid-a …
We hypothesized that among hospitalized acute coronary syndrome (ACS) patients, the addition of vildagliptin to subcutaneous insulin …
Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.
Zhang YS, Zheng YD, Yuan Y, Chen SC, Xie BC. Zhang YS, et al. Front Endocrinol (Lausanne). 2021 Oct 14;12:735824. doi: 10.3389/fendo.2021.735824. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34721294 Free PMC article.
Some drugs (omarigliptin, sitagliptin, vildagliptin, saxagliptin, empagliflozin, ertugliflozin, rosiglitazone, pioglitazone, and nateglinide) may increase the risk of fracture, while others (such as dulaglutide, exenatide, liraglutide, semaglutide, lixisenatide, linaglipti …
Some drugs (omarigliptin, sitagliptin, vildagliptin, saxagliptin, empagliflozin, ertugliflozin, rosiglitazone, pioglitazone, and nate …
247 results

Searches related to "vildagliptin"